FDA
approval
· 2022-03-30
FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
Summary
The FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company for HIV infection.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)